This edition we’re talking synthetic libraries: read on to see how we can save up to 8 months on immunisation alone compared with traditional approaches. Since November we’ve seen Dave attend Genesis in London, Ben go to PEGS, Barcelona, and Marion off to CAR-T, London. March will see our MRC iCASE PhD student, Natasha Spena continue her project at the University of Leicester. We’re proud to announce a new partnership with Arvinas, and finally, we ask: was our Director of Business Development, Dave Mead, correct about his biopharma predictions for 2023? And look to his predictions for 2023.
A selection of technical resources.
CIS display, a DNA-based in vitro selection technology for therapeutic peptides
CIS display is a DNA-based in vitro display technology that enables the display and selection of peptides and proteins from extremely large libraries…
ON Helix 6th July 2023, Cambridge, UK
Dave Mead our Director of Business Development is heading to ON Helix this July and we’re looking to find partners in the biotechnology space. ON Helix is a one day conference addressing key bio...
Festival of Biologics 10th – 12th October 2023, Basel
We’re looking forward to be attending the Festival of Biologics this coming autumn in Basel. Isogenica will be both eager to talk to companies in the biotech space for partnering opportunities as...
ELRIG Drug Discovery 18th – 19th October 2023
Two of our Scientists from the Research and Development team, Katherine Jones and Ziqian Yan are pleased to be attending ELRIG’s Drug Discovery conference on the 18th-19th October later this year....
BioEurope Spring 2023
Our Director of Business Development, Dave Mead recently attended BioEurope in Basel, meeting with colleagues old and new to discuss potential new partnerships and learn from peers in the biotech...
CAR-T London Spring 2023
Back in February 2023 our Director of Discovery, Marion Cubitt attended the 6th Annual CAR-TCR summit.
CIS display: In vitro selection of peptides from libraries of protein–DNA complexes
PNAS published February 23, 2004. 101 (9) 2806-2810
The structure of myeloid cell-specific TNF inhibitorsaffects their biological properties
Immunogenicity and humanization of single-domainantibodies
Senior Scientist (Assay development – Cell Biology / Immunology)
For more than twenty years, Isogenica has built deep expertise and knowledge about how to discover antibodies and develop them into drugs in partnership with some of the world’s most innovative biopharma companies. Now, we are leveraging that experience to build those drugs ourselves…
Small is beautiful – VHHs for next generation cell therapies
We’re experts on VHH antibodies. Read on to discover the advantages of using VHHs in CAR targeting, our recently launched ISOXTEND® technology, and how our VHHs are being tested in a potential new therapy for heart failure. We’re also delighted to announce that Marion Cubitt, our Director of Discovery, has been awarded a place on a prestigious RAEng scale-up accelerator programme.